Generalitat de Catalunya

TECHNOLOGY CENTERS IN CATALONIA

TECNIO certification and main R&D players in Catalonia


Header Tecnio
BREAST2TEST
Spanish Patent pending. International Patent pending(National phases).

Procedures for using the cell line HER2 + with dual resistance to Lapatinib and Trastuzumab breast cancer types for identifying drug candidates. There is nothing similar on the market. The technology is interesting for pharmaceutical companies specializing in breast cancer.

TECHNOLOGY DESCRIPTION

This Technology is based on a HER2 positive breast cancer cell line. This cell line is stable with dual resistance to Lapatinib and Trastuzumab and it also gets a new procedure for using the cell line to identify drug candidates.

The technology is a testing bench aiming to set up new drugs, and to reduce the costs of R&D related to breast cancer HER2+ which is resistent to the treatment with lapatinib and trastuzumab.

Breast cancer is the most common cancer among women, whose 30% of cases is HER2+ type, which in most of cases it develops resistance to the lapatinib and trastuzmab treatment. This makes the discovery of new drugs in such field possible.

BUSINESS OPPORTUNITY

It is the first pre-clinical model of "virtual" double resistant patient, this saves time and money compared with the traditional model. Tests can be done "in vitro", where non effective drugs are discarded, and "in vivo", where those that are toxic are discarded.

License. It is looking for licensing the technology or to pharmaceutical companies or to an exclusive licensee to hit pharmaceutical companies.

APPLICATION

Alternative treatments for this kind of cancer.

The target market which this technology is aiming to be the treatment of breast cancer. Growth rates of cancer treatment (in general) are on the rise, expecting to reach up to $ 64,000 million in 2016.

Biotechnology

Some sub-sectors in the field of "Health Industries".

STATE OF MATURITY
Research
Development
Exploitation

The product is ready to be used.

STATE OF INTELLECTUAL AND INDUSTRIAL PROPERTY

Spanish Patent pending. International Patent pending(National phases). Universitat de Girona (UdG) (100%).

ADDITIONAL MATERIAL
UDG_Unitat de Valorització
Marc Sabater i Armengou
972 418 965
TargetsLab
BREAST2TEST
Spanish Patent pending. International Patent pending(National phases).

Procedures for using the cell line HER2 + with dual resistance to Lapatinib and Trastuzumab breast cancer types for identifying drug candidates. There is nothing similar on the market. The technology is interesting for pharmaceutical companies specializing in breast cancer.

TECHNOLOGY DESCRIPTION

This Technology is based on a HER2 positive breast cancer cell line. This cell line is stable with dual resistance to Lapatinib and Trastuzumab and it also gets a new procedure for using the cell line to identify drug candidates.

The technology is a testing bench aiming to set up new drugs, and to reduce the costs of R&D related to breast cancer HER2+ which is resistent to the treatment with lapatinib and trastuzumab.

Breast cancer is the most common cancer among women, whose 30% of cases is HER2+ type, which in most of cases it develops resistance to the lapatinib and trastuzmab treatment. This makes the discovery of new drugs in such field possible.

BUSINESS OPPORTUNITY

It is the first pre-clinical model of "virtual" double resistant patient, this saves time and money compared with the traditional model. Tests can be done "in vitro", where non effective drugs are discarded, and "in vivo", where those that are toxic are discarded.

License. It is looking for licensing the technology or to pharmaceutical companies or to an exclusive licensee to hit pharmaceutical companies.

APPLICATION

Alternative treatments for this kind of cancer.

The target market which this technology is aiming to be the treatment of breast cancer. Growth rates of cancer treatment (in general) are on the rise, expecting to reach up to $ 64,000 million in 2016.

Biotechnology

Some sub-sectors in the field of "Health Industries".

STATE OF MATURITY
Research
Development
Exploitation

The product is ready to be used.

STATE OF INTELLECTUAL AND INDUSTRIAL PROPERTY

Spanish Patent pending. International Patent pending(National phases). Universitat de Girona (UdG) (100%).

ADDITIONAL MATERIAL
UDG_Unitat de Valorització
Marc Sabater i Armengou
972 418 965
TargetsLab